The In-Vivo-Effect of E-Aminocaproic Acid (EACA) on Human Plasma Fibrinolytic System

St Niewiarowski; Nina Wołosowicz

doi:10.1055/s-0038-1649451

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1966; 15(03/04): 491-500
DOI: 10.1055/s-0038-1649451

Originalarbeiten — Original Articles — Travaux Originaux

Schattauer GmbH

The In-Vivo-Effect of E-Aminocaproic Acid (EACA) on Human Plasma Fibrinolytic System

St Niewiarowski

¹Department of Physiological Chemistry, Medical School, Bialystok. Poland

,

Nina Wołosowicz

¹Department of Physiological Chemistry, Medical School, Bialystok. Poland

› Author Affiliations

Abstract

Summary

EACA was administered orally to 30 healthy volunteers in a single doses of 0.1 g per kg body weight. The level of this compound in blood plasma and its effect on the human plasma fibrinolytic system were investigated.

EACA is rapidly absorbed from the intestinal tract, its maximal level in the blood plasma being reached one hour later. The half life of this compound in the blood plasma amounted to two hours on the average.

The following changes in the plasma fibrinolytic system were observed : a) an inhibition of euglobulin fibrinolysis, which was most pronounced three hours after EACA ingestion ; b) a considerable increase in plasminogen, antiplasmin and antitrypsin activities (maximum-five hours after EACA) ; c) slight increase in fibrinogen level (maximum-five hours after EACA).

The conclusion has been reached that EACA induces a rise in endogenous inhibitors of the fibrinolytic system in the normal organism which may reinforce the hemostatic effect of this drug. The observed phenomena may be explained if we assume that the activation of the fibrinolytic system in the organism is continuous.

Full Text

References

References
1 Ablondi F. B, De Renzo E. G. Mechanism of Clot Lysis by streptokinase and effects of epsilon-aminocaproic acid. Proc. Soc. exp. Biol. (N. Y) 102: 717 1959;
2 Alkjaersig N, Fletcher A. P, Sherry S. E-amino caproic acid: an inhibitor of plasminogen activation. J. biol. Chem 234: 832 1959;
3 Amris A, Amris G. J. Turnover and distribution of ¹³¹iodine labelled human fibrinogen. Thrombos. Diathes. haemorrh. (Stuttg) 11: 404 1964;
4 Anderson L. Studies on fibrinolysis in urinary tract disease and its treatment with epsilonaminocaproic acid. Acta chir. scand. suppl. 301 1962;
5 Bar-Prcitkowska J, Niewiarowska M, Dobraczynska J. Zastosowanie kwasu E-amino - kapronowego w ginekologii i poloznictwie. Ginek. pol 35: 81 1964;
6 Blix S. The euglobulin method for estimation of fibrinolytic activity in streptokinase - activated plasma. Scand. J. clin. Lab. Invest 14: 528 1962;
7 Biduk K, Furman M. On the controlling function of the kidneys in fibrinolysis. Experientia (Basel) 18: 146 1962;
8 Buluk K, Malofiejew M. Otrzymywanie aktywatora fibrynolizy w nerce poza ustrojem (aktywator fibrynolizy w izolowanej nerce). Acta physiol, pol 14: 371 1963;
9 Celander D. R, Dale M, Guest M. M. The fibrinolytic system: a review of its therapeutic significance and control with particular emphasis on its inhibition by E-aminocaproic acid. Tex. Rep. Biol. Med 19: 16 1961;
10 Deutsch E, Marschner I. Antifibrinolysine. Folia haematol. N.F 08: 74 1963;
11 Gajewski J, Alexander B. Effect of epsilonaminocaproic acid on the turnover of labelled fibrinogen in rabbits. Circulât. Res 13: 432 1963;
12 KeJcwicJc R. A, Mackay M. E, Nance H. M, Record B. R. The purification of human fibrinogen. Biochem. J 60: 671 1955;
13 Kostro B, Prokopowicz J, Serwatko A. Badanie ostrej i przewleklej toksycznosci kwasu E-aminokapronowego. Acta physiol, pol 15: 439 1964;
14 Kowalski E, Kopec M, Niewiarowski S. Evaluation of the euglobulin method of determination of fibrinolysis. J. clin. Path 12: 215 1959;
15 Lewis J. H. Effects of epsilon amino caproic acid (EACA) on survival of fibrinogen I¹³¹ and on fibrinolytic and coagulation factors in dogs. Proc. Soc. exp. Biol. (N. Y) 114: 777 1963;
16 Lewis J. H, Ferguson J. H. Partial purification of human prothrombin and proconvertin, their characteristics and interaction. J. clin. Invest 32: 915 1953;
17 Lewis J. H, Doyle A. P. Effects of epsilon aminocaproic acid on coagulation and fibrinolytic mechanisms. J. Amer. med. Ass 188: 56 1964;
18 Mc G. P.Nicol. Disordered fibrinolytic activity and its control. Scot. med. J 07: 266 1962;
19 McNicol G. P, Fletcher A. P, Alkjaersig N, Sherry S. The absorption, distribution, and. excretion of E-aminocaproic acid following oral or intravenous administration to man. J. Lab. clin. Med 59: 15 1962;
20 Müllertz S. The plasmin activator system in human blood. Thrombosis and Embolism Proc. 1st Int. Conf.. Basel; 1954: 79.
21 Niewiarowska M, Mçgrzynowicz Z. Influence of dicoumarol derivatives on plasma fibrinolytic system. Thrombos. Diathes. haemorrh. (Stuttg) 03: 279 1959;
22 Niewiarowski S. L’adsorption des facteurs du systeme fibrinolytique par la bentonite. Path. Biol 07: 2557 1959;
23 Niewiarowski S. Untersuchungen über die hämostatische Wirkung von E - Aminokapr on - säure (EACA). Z. ges. inn. Med 20: 323 1965;
24 Niewiarowski S, Prokopowicz J, Poplawski A, Worowski K. Inhibition of dog fibrinolytic system in experimental tubular necrosis of kidney. Experientia (Basel) 20: 101 1964;
25 Nilsson I. M, Sjoerdsma A, Waldenstrom J. Antifibrinolytic activity and metabolism of E-aminocaproic acid in man. Lancet 1322 1960;
26 Nilsson I. M, Björkman S. E, Andersson L. Clinical experiences with E-aminocaproic acid (EACA) as an antifibrinolytic agent. Acta med. scand 170: 487 1961;
27 Norman P. S. Studies of the plasmin system. II. Inhibition of plasmin by serum or plasma. J. exp. Med 108: 53 1958;
28 Norman P. S, Hill B. M. Studies of the plasmin system. III. Physical properties of two inhibitors in plasma. J. exp. Med 108: 639 1958;
29 Okamoto S. Plasmin and antiplasmin. Their pathologic physiology. Keio J. Med 08: 211 1959;
30 Paraskewas M, Nilsson I. M, Martinson G. A method for determining serum inhibitors of plasminogen activation. Scand. J. clin. Lab. Invest 14: 138 1962;
31 Quick A. J. Hemorrhagic Diseases. Lea and Febiger. Philadelphia; 1954
32 Sato S, Ishibashi Y, Endo T, Watanabe K, Nakajima K. Clinical use of E-Amino-N-Caproic acid on methropathia haemorrhagica. Keio J. Med 08: 267 1959;
33 Schnitze H. E, Heimburger N, Heide K, Haupt H, Storiko K, Schwick H. G. Preparation and characterization of o^-trypsin inhibitor and a₂-plasmin inhibitor of human serum. Proc. 9th Congr. europ. Soc. Haemat., Lisbon.. 1963: 1315 Karger, Basel.:
34 Wolosowicz N, Niewiarowski S, Czerepko K. Method for determining E-Aminocaproic Acid (EACA) in blood plasma, based on the antifibrinolytic properties of this compound. Thrombos. Diathes. haemorrh. (Stuttg) 10: 309 1964;
35 Worowski K. Unpublished experiments..
36 Worowski K, Niewiarowski S, Prokopowicz J. Fibrinolysis and fibrinogen breakdown products (antithrombin VI) in renal venous blood (RVB) in dog. Thrombos. Diathes. haemorrh. (Stuttg) 12: 87 1964;
37 Zylber J, Blatt W. F, Jensen H. Mechanism of bovine plasminogen activation by human plasmin and streptokinase. Proc. Soc. exp. Biol. (IST. Y) 102: 755 1959;